Explore another way you may receive treatment.

Potential OPDIVO® (nivolumab) user fishing with his grandson.
Potential OPDIVO® (nivolumab) user fishing with his grandson.

Your fight against colorectal
cancer (MSI‑H/dMMR)
may
start or continue here

OPDIVO, alone or with YERVOY, is an FDA-approved immunotherapy option to treat advanced colorectal cancer (MSI-H/dMMR)

Actor portrayals.
OPDIVO or OPDIVO + YERVOY is not approved
for people younger than 12 years of age. OPDIVO Qvantig is not approved for people younger than 18 years of age.

Advanced colorectal cancer

OPDIVO + YERVOY is a treatment option for certain adults and children 12 years and older who have MSI-H/dMMR colorectal cancer that cannot be removed by surgery or has spread to other parts of the body (metastatic)

Previously treated colorectal cancer

If you or a loved one are receiving treatment with either OPDIVO + YERVOY or OPDIVO alone for previously treated colorectal cancer, you can find more information in the Medication Guide or speak to your doctor

See treatment plans and what to expect from an OPDIVO® IV infusion or OPDIVO® QVANTIG™ subcutaneous injection.
Explore another way you may receive treatment

You and your healthcare provider may have a choice between under-the-skin injections (subcutaneous injection) with OPDIVO Qvantig and intravenous (lV) infusions with OPDIVO

OPDIVO Qvantig cannot be used in combination with YERVOY. OPDIVO and OPDIVO Qvantig will not work for everyone. Individual results may vary.

Man exploring real patients stories of experiences with OPDIVO® (nivolumab) or other OPDIVO-based combinations.

Patient stories

Real patients share their experiences with OPDIVO and OPDIVO-based treatments

Frequently asked questions about treatment with OPDIVO® (nivolumab).

Have questions about treatment?

We have answers about getting treatment, monitoring, and more

Hands exploring cost information and financial help for OPDIVO® (nivolumab).

Cost information and financial help

Find information about cost and access to OPDIVO



466-US-2500009  03/25